Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

David Mischoulon, PH.D., M.D.

TitleAssociate Professor of Psychiatry
InstitutionMassachusetts General Hospital
DepartmentPsychiatry
AddressMassachusetts General Hospital
Suite 401
50 Staniford Street
Boston MA 02114
Phone617/724-5198
Fax617/726-7541

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sarris J, Nierenberg AA, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, Covino J, Fava M, Mischoulon D. Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. J Clin Psychopharmacol. 2013 Dec; 33(6):827-30.
    View in: PubMed
  2. Nyer M, Doorley J, Durham K, Yeung AS, Freeman MP, Mischoulon D. What is the Role of Alternative Treatments in Late-life Depression? Psychiatr Clin North Am. 2013 Dec; 36(4):577-96.
    View in: PubMed
  3. Kim B, Kang ES, Fava M, Mischoulon D, Soskin D, Yu BH, Lee D, Lee DY, Park HD, Jeon HJ. Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder. Psychiatry Res. 2013 Dec 30; 210(3):951-6.
    View in: PubMed
  4. Dording C, Cassiello C, King F, Pencina M, Fava M, Mischoulon D. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol. 2013 Sep; 28(5):238-44.
    View in: PubMed
  5. Jeon HJ, Hong JP, Fava M, Mischoulon D, Nyer M, Inamori A, Sohn JH, Seong S, Cho MJ. Childhood parental death and lifetime suicide attempt of the opposite-gender offspring in a nationwide community sample of Korea. Suicide Life Threat Behav. 2013 Dec; 43(6):598-610.
    View in: PubMed
  6. Edwards E, Mischoulon D, Rapaport M, Stussman B, Weber W. Building an evidence base in complementary and integrative healthcare for child and adolescent psychiatry. Child Adolesc Psychiatr Clin N Am. 2013 Jul; 22(3):509-29.
    View in: PubMed
  7. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80.
    View in: PubMed
  8. Cassano P, Chang T, Trinh NH, Baer L, Fava M, Mischoulon D. Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos. J Affect Disord. 2013 Sep 5; 150(2):578-84.
    View in: PubMed
  9. Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 2013 Sep-Oct; 54(5):488-92.
    View in: PubMed
  10. Mischoulon D, Freeman MP. Omega-3 Fatty acids in psychiatry. Psychiatr Clin North Am. 2013 Mar; 36(1):15-23.
    View in: PubMed
  11. Dording CM, Larocca RA, Hails KA, Vitolo OV, Wisniewski SR, Balasubramani GK, Trivedi M, Fava M, Mischoulon D. The effect of sildenafil on quality of life. Ann Clin Psychiatry. 2013 Feb; 25(1):3-10.
    View in: PubMed
  12. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
    View in: PubMed
  13. Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P, Fava M, Mischoulon D. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012 Dec; 32(6):787-96.
    View in: PubMed
  14. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. l-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials. Am J Psychiatry. 2012 Dec 1; 169(12):1267-74.
    View in: PubMed
  15. Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, Jacka FN, Schweitzer I. Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence. Evid Based Complement Alternat Med. 2012; 2012:809653.
    View in: PubMed
  16. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry. 2012 Dec; 17(12):1161-3.
    View in: PubMed
  17. Wu J, Yeung AS, Schnyer R, Wang Y, Mischoulon D. Acupuncture for depression: a review of clinical applications. Can J Psychiatry. 2012 Jul; 57(7):397-405.
    View in: PubMed
  18. Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86.
    View in: PubMed
  19. Sarris J, Fava M, Schweitzer I, Mischoulon D. St John's Wort (Hypericum perforatum) versus Sertraline and Placebo in Major Depressive Disorder: Continuation Data from a 26-Week RCT. Pharmacopsychiatry. 2012 Nov; 45(7):275-8.
    View in: PubMed
  20. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8.
    View in: PubMed
  21. Jeon HJ, Kang ES, Lee EH, Jeong EG, Jeon JR, Mischoulon D, Lee D. Childhood trauma and platelet brain-derived neurotrophic factor (BDNF) after a three month follow-up in patients with major depressive disorder. J Psychiatr Res. 2012 Jul; 46(7):966-72.
    View in: PubMed
  22. Mischoulon D, Brill CD, Ameral VE, Fava M, Yeung AS. A pilot study of acupuncture monotherapy in patients with major depressive disorder. J Affect Disord. 2012 Dec 10; 141(2-3):469-73.
    View in: PubMed
  23. Dording CM, Dalton ED, Pencina MJ, Fava M, Mischoulon D. Comparison of academic and nonacademic sites in multi-center clinical trials. J Clin Psychopharmacol. 2012 Feb; 32(1):65-8.
    View in: PubMed
  24. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
    View in: PubMed
  25. Cassano P, Fava M, Mischoulon D. Major depressive disorder with psychosis-like symptoms among Latinos. Psychiatr Serv. 2012; 63(5):482-7.
    View in: PubMed
  26. Mischoulon D. The impact of omega-3 fatty acids on depressive disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results? J Clin Psychiatry. 2011 Dec; 72(12):1574-6.
    View in: PubMed
  27. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76.
    View in: PubMed
  28. Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011 Oct; 31(5):597-602.
    View in: PubMed
  29. Mischoulon D. Can you recommend anything for dysthymia? Harv Ment Health Lett. 2011 Oct; 28(4):5.
    View in: PubMed
  30. Mischoulon D. What is maca root? Harv Ment Health Lett. 2011 Oct; 28(4):5.
    View in: PubMed
  31. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
    View in: PubMed
  32. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012 Feb; 136(3):1174-8.
    View in: PubMed
  33. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012 Jan; 73(1):81-6.
    View in: PubMed
  34. Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011 Aug; 72(8):1152-4.
    View in: PubMed
  35. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord. 2011 Aug-Sep; 13(5-6):454-65.
    View in: PubMed
  36. Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int Clin Psychopharmacol. 2011 Jul; 26(4):206-12.
    View in: PubMed
  37. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012 Oct; 27(7):518-21.
    View in: PubMed
  38. Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res. 2011 Jul; 45(7):931-41.
    View in: PubMed
  39. Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI. SAMe and sexual functioning. Eur Psychiatry. 2012 Aug; 27(6):451-4.
    View in: PubMed
  40. Mischoulon D, Eddy KT, Keshaviah A, Dinescu D, Ross SL, Kass AE, Franko DL, Herzog DB. Depression and eating disorders: treatment and course. J Affect Disord. 2011 May; 130(3):470-7.
    View in: PubMed
  41. Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011 Apr; 72(4):473-9.
    View in: PubMed
  42. Fava M, Mischoulon D. Evidence for folate in combination with antidepressants at initiation of therapy. J Clin Psychiatry. 2010 Nov; 71(11):e31.
    View in: PubMed
  43. Yeung AS, Ameral VE, Chuzi SE, Fava M, Mischoulon D. A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. J Affect Disord. 2011 Apr; 130(1-2):285-9.
    View in: PubMed
  44. Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71.
    View in: PubMed
  45. Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
    View in: PubMed
  46. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8.
    View in: PubMed
  47. Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7.
    View in: PubMed
  48. Iovieno N, Dalton ED, Fava M, Mischoulon D. Second-tier natural antidepressants: review and critique. J Affect Disord. 2011 May; 130(3):343-57.
    View in: PubMed
  49. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
  50. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010 Jun; 71(6):669-81.
    View in: PubMed
  51. Nierenberg AA, Rapaport MH, Schettler PJ, Howland RH, Smith JA, Edwards D, Schneider T, Mischoulon D. Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-V. CNS Neurosci Ther. 2010 Aug; 16(4):208-16.
    View in: PubMed
  52. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin North Am. 2009 Dec; 36(4):789-807, x.
    View in: PubMed
  53. Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94.
    View in: PubMed
  54. Mischoulon D, Pedrelli P, Wurtman J, Vangel M, Wurtman R. Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective disorder (SAD). CNS Neurosci Ther. 2010; 16(1):13-24.
    View in: PubMed
  55. Targum SD, Mischoulon D. The status of nutraceuticals for the treatment of depression. Psychiatry (Edgmont). 2009 Sep; 6(9):46-8.
    View in: PubMed
  56. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44.
    View in: PubMed
  57. Iosifescu DV, Greenwald S, Devlin P, Mischoulon D, Denninger JW, Alpert JE, Fava M. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol. 2009 Nov; 19(11):772-7.
    View in: PubMed
  58. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009; 70 Suppl 5:12-7.
    View in: PubMed
  59. Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
    View in: PubMed
  60. Mischoulon D, Fava M. Are nutritional supplements ready for prime time? J Clin Psychiatry. 2008 Sep; 69(9):1497-8.
    View in: PubMed
  61. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008 Oct 30; 161(1):116-20.
    View in: PubMed
  62. Howland RH, Schettler PJ, Rapaport MH, Mischoulon D, Schneider T, Fasiczka A, Delrahiem K, Maddux R, Lightfoot M, Nierenberg AA. Clinical features and functioning of patients with minor depression. Psychother Psychosom. 2008; 77(6):384-9.
    View in: PubMed
  63. Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008 Sep 15; 64(6):455-60.
    View in: PubMed
  64. Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, Papakostas GI, Dording CM, Sonawalla SB, Nierenberg AA, Alpert JE, Fava M. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45.
    View in: PubMed
  65. Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008; 14(3):182-91.
    View in: PubMed
  66. Yeung A, Mischoulon D, Alpert J, Ma Y, Fava M. Acupuncture for major depressive disorder: has its efficacy been disproved? J Clin Psychiatry. 2007 Oct; 68(10):1617; author reply 1617-8.
    View in: PubMed
  67. Petersen T, Fava M, Alpert JE, Vorono S, Sanders KM, Mischoulon D. Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates. Acad Psychiatry. 2007 Jul-Aug; 31(4):281-9.
    View in: PubMed
  68. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am. 2007 Mar; 30(1):51-68.
    View in: PubMed
  69. Mischoulon D, Raab MF. The role of folate in depression and dementia. J Clin Psychiatry. 2007; 68 Suppl 10:28-33.
    View in: PubMed
  70. Farabaugh A, Mischoulon D, Schwartz F, Pender M, Fava M, Alpert J. Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD. Depress Anxiety. 2007; 24(6):433-9.
    View in: PubMed
  71. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006 Dec; 67(12):1954-67.
    View in: PubMed
  72. Farabaugh AH, Sonawalla SB, Fava M, Pedrelli P, Papakostas GI, Schwartz F, Mischoulon D. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006 Jun; 21(4):221-5.
    View in: PubMed
  73. Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81.
    View in: PubMed
  74. Fraguas R, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M. Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry. 2006 Aug 1; 60(3):270-4.
    View in: PubMed
  75. Mischoulon D, Lagomasino IT, Harmon C. Atypical psychotic symptoms in a Hispanic population: diagnostic dilemmas and implications for treatment. Psychiatry (Edgmont). 2005 Oct; 2(10):38-46.
    View in: PubMed
  76. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
  77. Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
    View in: PubMed
  78. Farabaugh A, Fava M, Mischoulon D, Sklarsky K, Petersen T, Alpert J. Relationships between major depressive disorder and comorbid anxiety and personality disorders. Compr Psychiatry. 2005 Jul-Aug; 46(4):266-71.
    View in: PubMed
  79. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
  80. Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005 Mar; 20(2):87-91.
    View in: PubMed
  81. Yeung A, Kung WW, Murakami JL, Mischoulon D, Alpert JE, Nierenberg AA, Fava M. Outcomes of recognizing depressed Chinese American patients in primary care. Int J Psychiatry Med. 2005; 35(3):213-24.
    View in: PubMed
  82. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
  83. Farabaugh AH, Mischoulon D, Fava M, Green C, Guyker W, Alpert J. The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD). Acta Psychiatr Scand. 2004 Dec; 110(6):465-70.
    View in: PubMed
  84. Farabaugh A, Mischoulon D, Fava M, Guyker W, Alpert J. The overlap between personality disorders and major depressive disorder (MDD). Ann Clin Psychiatry. 2004 Oct-Dec; 16(4):217-24.
    View in: PubMed
  85. Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
  86. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
  87. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
  88. Yeung A, Kung WW, Chung H, Rubenstein G, Roffi P, Mischoulon D, Fava M. Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans. Gen Hosp Psychiatry. 2004 Jul-Aug; 26(4):256-60.
    View in: PubMed
  89. Papakostas GI, Ong├╝r D, Iosifescu DV, Mischoulon D, Fava M. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004 Mar; 14(2):135-42.
    View in: PubMed
  90. Mischoulon D, Beresin EV. "The Matrix": An allegory of the psychoanalytic journey. Acad Psychiatry. 2004; 28(1):71-7.
    View in: PubMed
  91. Yeung A, Chan R, Mischoulon D, Sonawalla S, Wong E, Nierenberg AA, Fava M. Prevalence of major depressive disorder among Chinese-Americans in primary care. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):24-30.
    View in: PubMed
  92. Mischoulon D, Opitz G, Kelly K, Fava M, Rosenbaum JF. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety. 2004; 19(1):43-50.
    View in: PubMed
  93. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
    View in: PubMed
  94. Perlis RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
  95. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003 Nov 1; 54(9):879-83.
    View in: PubMed
  96. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
  97. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE, Fava M, Nierenberg AA. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
    View in: PubMed
  98. Mischoulon D, Dougherty DD, Bottonari KA, Gresham RL, Sonawalla SB, Fischman AJ, Fava M. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Res. 2002 Dec 30; 116(3):151-61.
    View in: PubMed
  99. Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R, Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002 Dec; 63(12):1164-70.
    View in: PubMed
  100. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov; 76(5):1158S-61S.
    View in: PubMed
  101. Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002 Sep; 14(3):143-7.
    View in: PubMed
  102. Farabaugh A, Mischoulon D, Yeung A, Alpert J, Matthews J, Pava J, Fava M. Predictors of stable personality disorder diagnoses in outpatients with remitted depression. J Nerv Ment Dis. 2002 Apr; 190(4):248-56.
    View in: PubMed
  103. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002 Mar; 14(1):33-8.
    View in: PubMed
  104. Mischoulon D, McColl-Vuolo R, Howarth S, Lagomasino IT, Alpert JE, Nierenberg AA, Fava M. Management of major depression in the primary care setting. Psychother Psychosom. 2001 Mar-Apr; 70(2):103-7.
    View in: PubMed
  105. Mischoulon D, Fava M. Docosahexanoic acid and omega-3 fatty acids in depression. Psychiatr Clin North Am. 2000 Dec; 23(4):785-94.
    View in: PubMed
  106. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE. Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. J Psychosom Res. 2000 Sep; 49(3):183-7.
    View in: PubMed
  107. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition. 2000 Jul-Aug; 16(7-8):544-6.
    View in: PubMed
  108. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000 Jun; 45(5):476-81.
    View in: PubMed
  109. Mischoulon D. Antidepressants: choices and controversy. Health News. 2000 Jun; 6(6):4-5.
    View in: PubMed
  110. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):322-6.
    View in: PubMed
  111. Mischoulon D, Rosenbaum JF. The use of natural remedies in psychiatry: a commentary. Harv Rev Psychiatry. 1999 Jan-Feb; 6(5):279-83.
    View in: PubMed
  112. Rana B, Xie Y, Mischoulon D, Bucher NL, Farmer SR. The DNA binding activity of C/EBP transcription factor is regulated in the G1 phase of the hepatocyte cell cycle. J Biol Chem. 1995 Jul 28; 270(30):18123-32.
    View in: PubMed
  113. Rana B, Mischoulon D, Xie Y, Bucher NL, Farmer SR. Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response transcription factors. Mol Cell Biol. 1994 Sep; 14(9):5858-69.
    View in: PubMed
  114. Mischoulon D, Rana B, Kotliar N, Pilch PF, Bucher NL, Farmer SR. Differential regulation of glucose transporter 1 and 2 mRNA expression by epidermal growth factor and transforming growth factor-beta in rat hepatocytes. J Cell Physiol. 1992 Nov; 153(2):288-96.
    View in: PubMed
  115. Mischoulon D, Rana B, Bucher NL, Farmer SR. Growth-dependent inhibition of CCAAT enhancer-binding protein (C/EBP alpha) gene expression during hepatocyte proliferation in the regenerating liver and in culture. Mol Cell Biol. 1992 Jun; 12(6):2553-60.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Mischoulon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_